## Peter Bytzer

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1894284/publications.pdf Version: 2024-02-01



DETED RVTZED

#	Article	IF	CITATIONS
1	Empirical Second-Line Therapy in 5000 Patients of the European Registry on Helicobacter pylori Management (Hp-EuReg). Clinical Gastroenterology and Hepatology, 2022, 20, 2243-2257.	4.4	15
2	A positive diagnostic strategy is safe and saves endoscopies in patients with irritable bowel syndrome: A fiveâ€year followâ€up of a randomized controlled trial. Neurogastroenterology and Motility, 2021, 33, e14004.	3.0	8
3	European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients. Gut, 2021, 70, 40-54.	12.1	139
4	Expansion and persistence of antibiotic-specific resistance genes following antibiotic treatment. Gut Microbes, 2021, 13, 1-19.	9.8	24
5	Randomised clinical trial: a 12â€strain bacterial mixture versus faecal microbiota transplantation versus vancomycin for recurrent <i>Clostridioides difficile</i> infections. Alimentary Pharmacology and Therapeutics, 2021, 53, 999-1009.	3.7	25
6	Helicobacter pylori firstâ€line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on HÂpylori management (Hpâ€EuReg). Helicobacter, 2020, 25, e12686.	3.5	27
7	Mining, analyzing, and integrating viral signals from metagenomic data. Microbiome, 2019, 7, 42.	11.1	58
8	Systematic review with meta-analyses: does the pathogen matter in post-infectious irritable bowel syndrome?. Scandinavian Journal of Gastroenterology, 2019, 54, 546-562.	1.5	26
9	Use of proton pump inhibitors after antireflux surgery: a nationwide register-based follow-up study. Gut, 2014, 63, 1544-1549.	12.1	37
10	Metronidazole Therapy for Treating Dientamoebiasis in Children Is Not Associated With Better Clinical Outcomes: A Randomized, Double-Blinded and Placebo-Controlled Clinical Trial. Clinical Infectious Diseases, 2014, 58, 1692-1699.	5.8	51
11	Patients Suspected of Irritable Bowel Syndrome—Cross-Sectional Study Exploring the Sensitivity of Rome III Criteria in Primary Care. American Journal of Gastroenterology, 2013, 108, 972-980.	0.4	46
12	Burden of Upper Gastrointestinal Symptoms in Patients Receiving Low-Dose Acetylsalicylic Acid for Cardiovascular Risk Management. American Journal of Cardiovascular Drugs, 2013, 13, 27-35.	2.2	7
13	Analysis of Upper Gastrointestinal Adverse Events Among Patients Given Dabigatran in the RE-LY Trial. Clinical Gastroenterology and Hepatology, 2013, 11, 246-252.e5.	4.4	67
14	Dyspepsia as an adverse effect of drugs. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2010, 24, 109-120.	2.4	20
15	What Makes Individuals With Gastroesophageal Reflux Disease Dissatisfied With Their Treatment?. Clinical Gastroenterology and Hepatology, 2009, 7, 816-822.	4.4	32